Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

KRYSTAL BIOTECH, INC.

KRYSTAL BIOTECH, INC. logo

Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The Company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. In May 2023, VYJUVEK™ was approved by the US Food and Drug Administration (FDA) for the treatment of dystrophic epidermolysis bullosa (DEB). VYJUVEK is a non-invasive, topical, redosable gene therapy designed to treat DEB at the molecular level. Headquartered in Pittsburgh, Pennsylvania, the Company is led by an experienced management team, is fully-integrated, and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing, and commercialization.